CHAARTED

ADT + Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

Patient / Population Intervention / Exposition Comparaison Critère de jugement

In 790 patients with metastatic hormone-sensitive prostate cancer, ADT + docetaxel improved overall survival compared with ADT alone.

790

Schéma

Open-label RCT

Critère

Overall survival

Pertinence

RésultatOS 57.6 vs 44.0 months (HR 0.61). High-volume subgroup: 51.2 vs 34.4 months (HR 0.63). No clear benefit in low-volume at long-term follow-up.

Sweeney CJ, et al. N Engl J Med. 2015;373(8):737-746; Kyriakopoulos CE, et al. J Clin Oncol. 2018;36(11):1080-1087. 10.1056/NEJMoa1503747

Discussion et critique

Opened the era of intensification on top of ADT in mHSPC. STAMPEDE/LATITUDE and triplet regimens (ARASENS, PEACE-1) have built on this scaffold.